Treatment of HIV/Tuberculosis Co-Disease

HIV/结核病合并疾病的治疗

• 批准号: 7900782
• 负责人: Kiat Ruxrungtham
• 金额: $ 5.88万
• 依托单位: HIV-NAT, THE THAI RED CROSS AIDS RCH CTR
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-06-01 至 2011-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7900782
• 关键词: Anti-Retroviral Agents; Cambodia; Clinical; Clinical Management; Disease; HIV; HIV therapy; Immunologic Deficiency Syndromes; Infection; Inpatients; Methods; Newly Diagnosed; Outcome; Outpatients; Patients; Pharmaceutical Preparations; Phase; Randomized; Research; Safety; System; Testing; Thailand; Tuberculosis; Upper arm; antiretroviral therapy; chemotherapy; improved; open label; programs; tuberculosis treatment

Objectives To conduct a randomised, open label study to test whether a strategy of initiation of antiretroviral therapy shortly after commencing tuberculosis chemotherapy (2 weeks) achieves a significantly improved outcome when compared to a strategy in which antiretroviral therapy is deferred until the induction phase is complete (2 months) Specific aims ¿ To evaluate the efficacy, safety and tolerability of two strategies for the management of HIV related TB disease ¿ To improve the clinical management of patients with HIV/TB co-disease ¿ To establish a system of direct observation of therapy for HIV related TB Methods ¿ The study will be conducted in both inpatient and outpatient settings in Thailand and Cambodia. ¿ All patients newly diagnosed with first episode tuberculosis and co-infected with HIV will receive standardised TB short-course chemotherapy. ¿ Patients will be randomised to receive antiretroviral therapy to commence either early in the course of tuberculosis treatment (at two weeks) or deferred until TB therapy has been completed (at two months). ¿ Patients in both arms will receive the same combination of antiretroviral drugs

目标 进行一项随机、开放标签研究，以检测启动抗逆转录病毒治疗的策略是否 开始结核化疗后不久（2周）， 与将抗逆转录病毒治疗推迟到诱导期完成的策略相比， （2个月） 具体目标 评估两种治疗HIV相关结核病策略的有效性、安全性和耐受性 疾病 改善艾滋病毒/结核病合并症患者的临床管理 建立艾滋病毒相关结核病治疗直接观察系统 方法 该研究将在泰国和柬埔寨的住院和门诊环境中进行。 所有新诊断为首次发病结核病并合并感染艾滋病毒的患者将接受 标准化结核病短程化疗。 患者将被随机分配接受抗逆转录病毒治疗， 结核病治疗（两周）或推迟到结核病治疗完成（两个月）。 两组患者将接受相同的抗逆转录病毒药物组合